928 related articles for article (PubMed ID: 18413337)
21. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients.
Ferreri AJ; Reni M; Dell'Oro S; Ciceri F; Bernardi M; Camba L; Ponzoni M; Terreni MR; Tomirotti M; Spina M; Villa E
Oncology; 2001; 60(2):134-40. PubMed ID: 11244328
[TBL] [Abstract][Full Text] [Related]
22. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment.
Young RC; Longo DL; Glatstein E; Ihde DC; Jaffe ES; DeVita VT
Semin Hematol; 1988 Apr; 25(2 Suppl 2):11-6. PubMed ID: 2456618
[TBL] [Abstract][Full Text] [Related]
23. [Chemo-radiotherapy for malignant brain tumors].
Kochi M; Ushio Y
Gan To Kagaku Ryoho; 2002 May; 29(5):669-76. PubMed ID: 12040669
[TBL] [Abstract][Full Text] [Related]
24. ProMACE-MOPP combination chemotherapy for diffuse lymphomas.
Fisher RI; Young RC; Longo D; DeVita VT
Semin Oncol; 1985 Mar; 12(1 Suppl 2):29-32. PubMed ID: 2579441
[TBL] [Abstract][Full Text] [Related]
25. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy.
Pels H; Schmidt-Wolf IG; Glasmacher A; Schulz H; Engert A; Diehl V; Zellner A; Schackert G; Reichmann H; Kroschinsky F; Vogt-Schaden M; Egerer G; Bode U; Schaller C; Deckert M; Fimmers R; Helmstaedter C; Atasoy A; Klockgether T; Schlegel U
J Clin Oncol; 2003 Dec; 21(24):4489-95. PubMed ID: 14597744
[TBL] [Abstract][Full Text] [Related]
26. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma.
Cheng T; Forsyth P; Chaudhry A; Morris D; Glück S; Russell JA; Stewart DA
Bone Marrow Transplant; 2003 Apr; 31(8):679-85. PubMed ID: 12692608
[TBL] [Abstract][Full Text] [Related]
27. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy.
Mead GM; Bleehen NM; Gregor A; Bullimore J; Shirley D; Rampling RP; Trevor J; Glaser MG; Lantos P; Ironside JW; Moss TH; Brada M; Whaley JB; Stenning SP
Cancer; 2000 Sep; 89(6):1359-70. PubMed ID: 11002232
[TBL] [Abstract][Full Text] [Related]
28. Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.
Ichikawa T; Kurozumi K; Michiue H; Ishida J; Maeda Y; Kondo E; Kawasaki A; Date I
Clin Neurol Neurosurg; 2014 Dec; 127():106-11. PubMed ID: 25459253
[TBL] [Abstract][Full Text] [Related]
29. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
[TBL] [Abstract][Full Text] [Related]
30. Sequential multidrug chemotherapy (CHOP-VA-MB) in patients with high-grade non-Hodgkin's lymphoma--a 20-year follow-up.
Björkholm M; Celsing F; Johansson E;
Ann Hematol; 2006 Oct; 85(10):731-3. PubMed ID: 16838163
[No Abstract] [Full Text] [Related]
31. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M
Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496
[TBL] [Abstract][Full Text] [Related]
32. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
Noordijk EM; Carde P; Dupouy N; Hagenbeek A; Krol AD; Kluin-Nelemans JC; Tirelli U; Monconduit M; Thomas J; Eghbali H; Aleman BM; Bosq J; Vovk M; Verschueren TA; Pény AM; Girinsky T; Raemaekers JM; Henry-Amar M
J Clin Oncol; 2006 Jul; 24(19):3128-35. PubMed ID: 16754934
[TBL] [Abstract][Full Text] [Related]
33. Combined therapy in the treatment of primary mediastinal B-cell lymphoma: conventional versus escalated chemotherapy.
Avilés A; García EL; Fernández R; Gonzalez JL; Neri N; Díaz-Maqueo JC
Ann Hematol; 2002 Jul; 81(7):368-73. PubMed ID: 12185505
[TBL] [Abstract][Full Text] [Related]
34. Primary mediastinal large B-cell lymphoma: results of intensive chemotherapy regimens (MACOP-B/VACOP-B) plus involved field radiotherapy on 53 patients. A single institution experience.
Mazzarotto R; Boso C; Vianello F; Aversa MS; Chiarion-Sileni V; Trentin L; Zambello R; Muzzio PC; Fiore D; Sotti G
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):823-9. PubMed ID: 17379431
[TBL] [Abstract][Full Text] [Related]
35. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
36. PROMACE-MOPP and intrathecal chemotherapy for CNS lymphomas.
Dent S; Eapen L; Girard A; Hugenholtz H; DaSilva V; Stewart DJ
J Neurooncol; 1996 Apr; 28(1):25-30. PubMed ID: 8740588
[TBL] [Abstract][Full Text] [Related]
37. Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma.
Korfel A; Martus P; Nowrousian MR; Hossfeld DK; Kirchen H; Brücher J; Stelljes M; Birkmann J; Peschel C; Pasold R; Fischer L; Jahnke K; Thiel E;
Br J Haematol; 2005 Jan; 128(2):177-83. PubMed ID: 15638851
[TBL] [Abstract][Full Text] [Related]
38. Consolidation radiotherapy in primary central nervous system lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy.
Ferreri AJ; Verona C; Politi LS; Chiara A; Perna L; Villa E; Reni M
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):169-75. PubMed ID: 20584577
[TBL] [Abstract][Full Text] [Related]
39. Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation.
Chow LM; Nathan PC; Hodgson DC; Jenkin D; Weitzman S; Grant RM; Manson D; Bross A; Doyle JJ; Danjoux C; Greenberg ML
J Clin Oncol; 2006 Dec; 24(36):5735-41. PubMed ID: 17179107
[TBL] [Abstract][Full Text] [Related]
40. [Treatment option and outcome for patients with primary non-Hodgkin's lymphoma of the nasal cavity].
Yao B; Li YX; Song YW; Jin J; Liu YP; Wang WH; Wang SL; Sun YT; Yu ZH; Liu XF
Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):58-61. PubMed ID: 16737624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]